Slovenia has started using monoclonal antibody treatment in some patients with covid-19.
The country received 1,000 doses of an experimental drug developed by US biotech company Regeneron as part of an agreement with the European Union.
The drug is licensed by the Drug Agency in Slovenia and is given to patients with severe symptoms in the early stages.
At the beginning of July, Slovenia expressed interest in purchasing 1,000 doses of the drug with monoclonal antibody “Sotromivab”, produced by the British pharmaceutical company GSK.
Last week, the director of the local Institute of Public Health made pessimistic forecasts that Slovenia would face a catastrophic state of health this winter if the vaccination rate did not rise.
So far, 40.7 percent of the total population has been fully vaccinated.
